Table 2.
Correlation between end-stage renal disease patients’ clinical features and erythropoietin (EPO) responsiveness
| EPO responders | EPO non-responders | P valuea | |
|---|---|---|---|
| Age (yr) | 59.0 ± 10.8 | 56.7 ± 9.3 | 0.746 |
| Ferritin (mg/dL) | 262.2 ± 117.3 | 430.7 ± 326.5 | 0.327 |
| Fe (μg/dL) | 71.8 ± 22.8 | 61.7 ± 17.9 | 0.507 |
| TIBC (μg/dL) | 258.0 ± 22.0 | 228 ± 3.6 | 0.080 |
| Alb (g/dL) | 4.2 ± 0.3 | 4.4 ± 0.1 | 0.355 |
| MCV (fL) | 92.8 ± 4.3 | 91.3 ± 2.1 | 0.584 |
| PTH (pg/mL) | 256.8 ± 102.1 | 455.3 ± 320.1 | 0.248 |
| Kt/V | 1.4 ± 0.3 | 1.6 ± 0.3 | 0.506 |
| Hb (g/dL) | 11.7 ± 0.9 | 9.9 ± 0.6 | 0.048b |
a P values were calculated by asymptotic two-sample Fisher-Pitman permutation test. TIBC total iron-binding capacity, Alb albumin, MCV mean corpuscular volumn, PTH parathyroid hormone, Kt/V (dialyzer clearance of urea)×(dialysis time)/(volume of distribution of urea); Hb, hemoglobin. b P-value < 0.05